- Home
- BRN vs NEUP Comparison
BRN vs NEUP Comparison
Compare BRN & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRN
- NEUP
- Stock Information
- Founded
- BRN 1956
- NEUP 1996
- Country
- BRN United States
- NEUP United States
- Employees
- BRN N/A
- NEUP N/A
- Industry
- BRN Oil & Gas Production
- NEUP
- Sector
- BRN Energy
- NEUP
- Exchange
- BRN Nasdaq
- NEUP Nasdaq
- Market Cap
- BRN 13.9M
- NEUP 12.7M
- IPO Year
- BRN N/A
- NEUP N/A
- Fundamental
- Price
- BRN $1.25
- NEUP $7.72
- Analyst Decision
- BRN
- NEUP Strong Buy
- Analyst Count
- BRN 0
- NEUP 1
- Target Price
- BRN N/A
- NEUP $21.00
- AVG Volume (30 Days)
- BRN 1.4M
- NEUP 30.4K
- Earning Date
- BRN 08-12-2025
- NEUP 08-15-2025
- Dividend Yield
- BRN N/A
- NEUP N/A
- EPS Growth
- BRN N/A
- NEUP N/A
- EPS
- BRN N/A
- NEUP 0.00
- Revenue
- BRN $19,387,000.00
- NEUP $15,662,715.00
- Revenue This Year
- BRN N/A
- NEUP N/A
- Revenue Next Year
- BRN N/A
- NEUP N/A
- P/E Ratio
- BRN N/A
- NEUP $4,532.08
- Revenue Growth
- BRN N/A
- NEUP N/A
- 52 Week Low
- BRN $1.08
- NEUP $2.90
- 52 Week High
- BRN $2.53
- NEUP $126.00
- Technical
- Relative Strength Index (RSI)
- BRN 48.63
- NEUP N/A
- Support Level
- BRN $1.08
- NEUP N/A
- Resistance Level
- BRN $1.22
- NEUP N/A
- Average True Range (ATR)
- BRN 0.09
- NEUP 0.00
- MACD
- BRN -0.01
- NEUP 0.00
- Stochastic Oscillator
- BRN 34.02
- NEUP 0.00
About BRN Barnwell Industries Inc.
Barnwell Industries Inc is an oil and gas firm. Its areas of operations include acquiring, developing, producing, and selling oil and natural gas. The company acquires and develops crude oil and natural gas assets. The company's operating segment includes Oil and natural gas, Contract drilling, Land investment, and Others. It generates maximum revenue from the Oil and natural gas segment. It operates in two geographical segments the United States, which generates a majority of revenue, and Canada.
About NEUP Neuphoria Therapeutics Inc. Common Stock
Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.